Skip to main content

Author: Customer Service

Beyond Meat® to Report Third Quarter 2025 Financial Results on November 10, 2025 and Hold Conference Call on November 11, 2025

EL SEGUNDO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — As previously announced, Beyond Meat, Inc. (NASDAQ: BYND) (“Beyond Meat” or “the Company”), a leader in plant-based meat, will host its conference call to discuss its financial results for the third quarter ended September 27, 2025 on Tuesday, November 11, 2025 at 5:00 p.m. Eastern, 2:00 p.m. Pacific. However, the Company announced today that it will now report its financial results for the third quarter ended September 27, 2025 on Monday, November 10, 2025, one day earlier than previously indicated. The adjustment has been made in recognition of the Veterans Day holiday, during which the U.S. Securities and Exchange Commission (“SEC”) will be closed. As previously announced, investors interested in participating in the live call on Tuesday, November 11, 2025 can dial 412-902-4255. There...

Continue reading

AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XR Most (85%) participants taking AUSTEDO or AUSTEDO XR in conjunction with their mental health medications reported that their mental health condition remained stable or improved Teva is committed to truly understanding and empowering individuals living with TD to help improve their TD and regain their independencePARSIPPANY, N.J., and TEL AVIV, Israel, Nov. 07, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of new data from the ongoing, real-world IMPACT-TD Registry. The findings demonstrate that treatment with AUSTEDO...

Continue reading

Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Decrease In October 2025 of 0.8% Compared to 2024

GUADALAJARA, Mexico, Nov. 07, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for October 2025, compared with October 2024. During this period, the total number of terminal passengers at GAP’s 12 Mexican airports increased by 0.7%, compared to October 2024. Guadalajara and Puerto Vallarta airports presented an increase in passenger traffic of 2.1% and 1.7%, respectively, while Tijuana, and Los Cabos airports decreased 4.2%, and 2.1%, respectively. Regarding Jamaica’s airports, Montego Bay Airport decreased by 17.6%, while Kingston declined by 13.0%, due to the impacts of Hurricane Melissa.Domestic Terminal Passengers (in thousands):             Airport Oct-24 Oct-25 % Change Jan – Oct...

Continue reading

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session – RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company developing therapies to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that clinical data for lorundrostat were presented at the American Society of Nephrology (ASN) Kidney Week 2025. Findings included a late-breaking oral presentation of the Phase 2 Explore-CKD trial and recognition of the pivotal Phase 3 Launch-HTN trial in the “Best of the Journal of the American Medical Association (JAMA) and the New...

Continue reading

Rocket Doctor Grants RSUs and Stock Options

Vancouver, BC, Nov. 07, 2025 (GLOBE NEWSWIRE) — Rocket Doctor AI Inc. (CSE: AIDR, OTC: AIRDF, Frankfurt: 939) (“Rocket Doctor AI”) announces that it has granted an aggregate 831,356 restricted share units (“RSUs”) and 20,964 stock options (“Options”) to consultants and employees of the Company and its subsidiary, Rocket Doctor Inc. The Options are each exercisable for one common share of the Company at an exercise price of C$0.82 per share for a period of three years from the grant date and subject to vesting provisions. 325,000 RSUs are valid for a term of two years and 506,356 RSUs are valid for a term of three years. 203,000 RSUs vest immediately and 628,356 are subject to vesting provisions.  All Options and RSUs are subject to the terms of the Company’s equity plans and applicable securities law hold periods. About Rocket...

Continue reading

Legacy Housing Corporation Reports Third Quarter 2025 Financial and Operating Results

Legacy Housing’s book value per share rose by 10.2% year-over-year, reflecting ongoing financial resilience. BEDFORD, Texas, Nov. 07, 2025 (GLOBE NEWSWIRE) — Legacy Housing Corporation (“Legacy Housing” or the “Company,” Nasdaq: LEGH), a leading manufacturer of community-focused manufactured homes, today announced financial results for the third quarter ended September 30, 2025. The Company reported product sales of $28.8 million, a decrease of 4.6% compared to the same period last year. The quarter saw a delivery of 420 floor sections, down from 475 in the prior-year period, continuing a trend of lower unit volumes with increased net revenue per unit. Despite these challenges, Legacy Housing’s book value per share(1) rose by 10.2% year-over-year, reflecting ongoing financial resilience. Following the end of the quarter, Legacy Housing...

Continue reading

Summit Royalties Announces Appointment of Jerrold Annett as Chairman; Trading to Commence on Venture Exchange; Other Corporate Updates

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Summit Royalties Ltd. (TSXV: SUM) (the “Corporation” or “Summit Royalties“) is pleased to announce corporate updates in connection with the recently completed go-public transaction by way of a reverse takeover (the “RTO“). Commencement of Trading on the TSX Venture Exchange In connection with the closing of the RTO and further to its news release on November 5, 2025 (titled “Summit Royalties Completes Go-Public Transaction”), the common shares of the Corporation (the “Common Shares“) are scheduled to commence trading on the TSX Venture Exchange (the “Exchange“) at market open on Monday, November 10, 2025, under the symbol “SUM”. In anticipation of commencement of trading on the Exchange, the Common Shares...

Continue reading

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01’s already strong data packageCOPENHAGEN, Denmark, November 7, 2025 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces new data exploring immune responses following treatment with AI-designed personalized cancer vaccine EVX-01. The data was presented today in a poster session at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor, Maryland. Developed with Evaxion’s AI-Immunology™ platform, EVX-01 is designed to target multiple...

Continue reading

Dorel Reports Third Quarter 2025 Results

Dorel Juvenile delivers resilient third quarter financial results amid market challenges Dorel Home restructuring on plan New financing arrangements in place strengthen Company’s financial positionMONTRÉAL, Nov. 07, 2025 (GLOBE NEWSWIRE) — Dorel Industries Inc. (TSX: DII.B, DII.A) today announced its financial results for the third quarter and nine months ended September 30, 2025. Third quarter revenue was US$298.6 million, compared to US$354.2 million, a decrease of 15.7% from the same period a year ago. Reported net loss was US$47.4 million or US$1.45 per diluted share, compared to US$21.9 million or US$0.67 per diluted share last year. Adjusted net loss1 for 2025 was US$29.8 million or US$0.91 per diluted share as compared to US$20.2 million or US$0.62 per diluted share last year. Revenue for the nine months was US$911.4...

Continue reading

Constellation Software Inc. Announces Results for the Third Quarter Ended September 30, 2025 and Declares Quarterly Dividend

TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the third quarter ended September 30, 2025 and declared a $1.00 per share dividend payable on January 12, 2026 to all common shareholders of record at close of business on December 19, 2025. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated. The following press release should be read in conjunction with the Company’s Unaudited Condensed Consolidated Interim Financial Statements for the three and nine months ended September 30, 2025 and the accompanying notes, our Management Discussion and Analysis for the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.